Observational studySupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023
Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia.
Observational study in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Trends in the Use of Anamorelin Hydrochloride for Cancer Cachexia: Examining the Timing of Anamorelin Initiation.Annals of nutrition & metabolism · 2026Article
- Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria.Journal of cachexia, sarcopenia and muscle · 2026Article
- Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Essential Updates 2023/2024: Recent Advances of Multimodal Approach in Patients for Gastric Cancer.Annals of gastroenterological surgery · 2025Review
- Effect of anamorelin treatment duration on survival of patients with cancer cachexia: A retrospective study.Molecular and clinical oncology · 2025Article
- Article
- Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status.Internal medicine (Tokyo, Japan) · 2025Article
- Significance of Neutrophil-to-Lymphocyte Ratio in Predicting the Efficacy of Anamorelin for Cancer Cachexia.Cureus · 2025Article
- Anamorelin for the Treatment of Cancer Anorexia-Cachexia Syndrome.Current oncology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCancer-associated cachexia, a multifactorial syndrome involving loss of muscle mass and anorexia, is an unremitting problem for cancer patients. Anamorelin has become available for cancer-associated cachexia, but early discontinuation is common in clinical practice. This study aimed to explore factors related to the early discontinuation of anamorelin and its relationship to survival. PATIENTS AND
methodsThis prospective, observational study of multimodal clinical practice involved patients who took anamorelin (100 mg) for cancer-associated cachexia at Aichi Medical University Hospital between 14 May 2021 and 31 March 2022. In July 2022, clinical data were extracted from electronic clinical records. Patients who discontinued anamorelin less than 4 weeks after initiation were defined as the early discontinuation group, and their clinical data and survival time were compared with those of the continuation group. This study was approved by the Ethics Committee of the university (approval no. 2021-124).
resultsOf the 42 patients treated with anamorelin, 40 (median age 72.5 years, median BMI 18.7 kg/m
conclusionWorse PS and low PNI were associated with early discontinuation of anamorelin. Longer survival time was observed in the continuation group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.